Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0

Social Author Image

https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg

Tweet Author

Social Author Name

Richard Conway

Tweet Content

Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0.90), tocizilumab (aHR 0.93), tofacitinib (aHR 0.69) vs rituximab. @RheumNow #ACR24 Abstr#1713 https://t.co/fbE8xAnzQ2 https://t.co/uwzH8oAyAT

Links

Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Ar… https://acrabstracts.org/abstract/comparisons-of-non-tnfi-biologic-and-targeted…

https://x.com/RichardPAConway/status/1858242203380003024/photo/1

Show on Archive Page

On

Display in Search Results

On

PDQ

Off

Topics

Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0

Do you get our email newsletter?